Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD4+ T-cell receptor (TCR) specific for Der p 2–MHC class II complexes is a pivotal mediator in the development and persistence of house dust mite (HDM) allergy. Der p 2 is a major 14-kDa allergen from Dermatophagoides pteronyssinus that possesses structural homology to MD-2, allowing it to facilitate TLR4 signaling and promote potent Th2-biased immune responses (PMID: 19633648). When Der p 2 is internalized and processed by antigen-presenting cells, its peptide fragments are displayed on MHC class II molecules for recognition by these specific TCRs. This interaction leads to the activation of CD4+ T cells, which in allergic individuals secrete cytokines such as IL-4, IL-5, and IL-13, driving IgE production and chronic eosinophilic inflammation in the airways (PMID: 30103050). Therapeutic strategies targeting this TCR-MHC interaction, such as allergen-specific immunotherapy (AIT), aim to induce immunological tolerance by promoting the expansion of regulatory T cells (Tregs) and shifting the cytokine profile away from Th2 dominance (PMID: 28213450). The use of MHC II tetramers to track these specific T-cell populations has become a vital tool for monitoring the efficacy of desensitization treatments and understanding the mechanisms of immune deviation.
Induction of immune tolerance through allergen-specific immunotherapy (AIT), leading to T-cell anergy, deletion, or immune deviation from a Th2-dominated profile to a Th1 or regulatory T-cell (Treg) profile (PMID: 28213450).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4+ T-cell receptor specific for Dermatophagoides pteronyssinus allergen 2–MHC class II complex (Der p 2-specific TCR).